GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Treasury Stock

Contineum Therapeutics (Contineum Therapeutics) Treasury Stock : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Contineum Therapeutics's treasury stock for the quarter that ended in Mar. 2024 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Contineum Therapeutics Treasury Stock Historical Data

The historical data trend for Contineum Therapeutics's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics Treasury Stock Chart

Contineum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Treasury Stock
- - -

Contineum Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Treasury Stock Get a 7-Day Free Trial - - - - -

Contineum Therapeutics Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Contineum Therapeutics (Contineum Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Treasury Stock
Comparable Companies
Traded in Other Exchanges
N/A
Address
10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Website
https://www.contineum-tx.com
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics (Contineum Therapeutics) Headlines

From GuruFocus

Contineum Therapeutics Announces Pricing of Initial Public Offering

By GlobeNewswire • 04-05-2024